Infection Control News

Candida auris is an emerging multidrug-resistant yeast causing nosocomial infections. First identified in 2009 in Japan, C. auris has now also been isolated in North America, South America, Europe, Africa, the Middle East and East Asia.

There has been a rebound in cases of tuberculosis in the United States, according to the CDC, with the largest increase occurring among children aged 4 years or younger.

The FDA recently approved Rezzayo, a weekly injectable treatment for adults with candidemia and invasive candidiasis.

SEATTLE — An intervention called LinkUP improved rates of COVID-19 testing and vaccination referral acceptance among people who inject drugs, with increased impact among those experiencing homeless, researchers found.

The federal court ruling against requiring health care insurers to cover PrEP could result in more than 2,000 new and preventable HIV infections among at-risk populations within 12 months of the ruling.

Throughout the COVID-19 pandemic, World TB Day, which is observed each year on March 23, has marked the need for more — more research, more testing, more treatment options, and more access for patients globally.

The FDA approved rezafungin for injection to treat candidemia and invasive candidiasis in adults, offering a new treatment for people with limited or no other options.

Cases of tuberculosis increased in the U.S. in 2022 but did not return to pre-pandemic levels, according to data published in a Morbidity and Mortality Weekly Report ahead of World TB Day.

Candida auris cases and transmission have dramatically increased in recent years, with 17 states identifying their first case from 2019 to 2021, according to a study published in Annals of Internal Medicine.

New research shows that the war in Ukraine is increasing the spread of HIV in the region, as a high number of people with HIV are fleeing to surrounding nations.